Oxytocin C-terminal tripeptide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597896

CAS#: 2002-44-0

Description: Oxytocin C-terminal tripeptide is shown to be effective in treating human depression with greater efficacy and faster onset of action than traditional anti-depressants. Also, it is used in the synthesis of novel analogs to be tested for their ability to enhance the binding of [3H]-N-propylnorapomorphine to short isoform of human dopamine D2 receptors.


Chemical Structure

img
Oxytocin C-terminal tripeptide
CAS# 2002-44-0

Theoretical Analysis

MedKoo Cat#: 597896
Name: Oxytocin C-terminal tripeptide
CAS#: 2002-44-0
Chemical Formula: C13H24N4O3
Exact Mass: 284.1848
Molecular Weight: 284.36
Elemental Analysis: C, 54.91; H, 8.51; N, 19.70; O, 16.88

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Oxytocin C-terminal tripeptide; MIF-I; MIF I; MIFI; Melanostatin I (ox); Melanocyte-stimulating hormone release-inhibiting factor I (ox);

IUPAC/Chemical Name: (S)-N-((S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide

InChi Key: NOOJLZTTWSNHOX-UWVGGRQHSA-N

InChi Code: InChI=1S/C13H24N4O3/c1-8(2)6-10(12(19)16-7-11(14)18)17-13(20)9-4-3-5-15-9/h8-10,15H,3-7H2,1-2H3,(H2,14,18)(H,16,19)(H,17,20)/t9-,10-/m0/s1

SMILES Code: O=C(N)CNC([C@H](CC(C)C)NC([C@H]1NCCC1)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 284.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Szabó G, Kovács GL, Baláspiri L, Telegdy G. D-pipecolyl-leucyl-glycinamide, a substituted tripeptide analogue of the C-terminal part of oxytocin, influences tolerance to and dependence on ethanol in mice. Alcohol Drug Res. 1987;7(2):99-105. PubMed PMID: 3778581.

2: Reed LL, Johnson PL. Solid state conformation of the C-terminal tripeptide of oxytocin, L-Pro-L-Leu-Gly-NH2 0.5H2O. J Am Chem Soc. 1973 Oct 31;95(22):7523-4. PubMed PMID: 4747887.

3: Budesínský M, Ragnarsson U, Lankiewicz L, Grehn L, Slaninová J, Hlavácek J. Synthesis and utilization of 13C and 15N backbone-labeled proline: NMR study of synthesized oxytocin with backbone-labeled C-terminal tripeptide amide. Amino Acids. 2005 Aug;29(2):151-60. Epub 2005 Mar 30. PubMed PMID: 15791394.

4: Petersson M, Uvnäs-Moberg K. Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels. Physiol Behav. 2004 Dec 15;83(3):475-81. PubMed PMID: 15581670.

5: Burgeon E, Chapleur M, Schoenen J, Remichius D, Legros JJ, Geenen V, Robert F. Monoclonal antibodies to oxytocin: production and characterization. J Neuroimmunol. 1991 Mar;31(3):235-44. PubMed PMID: 1995653.

6: Kovács CL, Van Ree JM. Behaviorally active oxytocin fragments simultaneously attenuate heroin self-administration and tolerance in rats. Life Sci. 1985 Nov 18;37(20):1895-900. PubMed PMID: 4058258.

7: Ukena K, Oumi T, Matsushima O, Ikeda T, Fujita T, Minakata H, Nomoto K. Effects of annetocin, an oxytocin-related peptide isolated from the earthworm Eisenia foetida, and some putative neurotransmitters on gut motility of the earthworm. J Exp Zool. 1995 Jun 15;272(3):184-93. PubMed PMID: 7790842.

8: Szabó G, Kovács GL, Székeli S, Baláspiri L, Telegdy G. C-terminal fragments of oxytocin (prolyl-leucyl-glycinamide and Z-prolyl-D-leucine) attenuate the development of tolerance to ethanol. Acta Physiol Hung. 1987;69(1):115-22. PubMed PMID: 2884803.

9: Van Ree JM, De Wied D. Modulation of heroin self-administration by neurohypophyseal principles. Eur J Pharmacol. 1977 May 15;43(2):199-202. PubMed PMID: 872873.

10: Liwo A, Tempczyk A, Ołdziej S, Shenderovich MD, Hruby VJ, Talluri S, Ciarkowski J, Kasprzykowski F, Lankiewicz L, Grzonka Z. Exploration of the conformational space of oxytocin and arginine-vasopressin using the electrostatically driven Monte Carlo and molecular dynamics methods. Biopolymers. 1996 Feb;38(2):157-75. PubMed PMID: 8589250.

11: Altstein M, Gainer H. Differential biosynthesis and posttranslational processing of vasopressin and oxytocin in rat brain during embryonic and postnatal development. J Neurosci. 1988 Nov;8(11):3967-77. PubMed PMID: 3183709.

12: Chini B, Mouillac B, Ala Y, Balestre MN, Cotte N, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, et al. Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family. Adv Exp Med Biol. 1995;395:321-8. PubMed PMID: 8713982.

13: Irokawa A, Tominaga M. A methodological study of the enzymatic synthesis of the tripeptide Z-Cys(Bzl)-Tyr-Ile-OtBu. Pept Res. 1991 Nov-Dec;4(6):340-6. PubMed PMID: 1821169.

14: Walter R, Neidle A, Marks N. Significant differences in the degradation of pro-leu-gly-nH2 by human serum and that of other species (38484). Proc Soc Exp Biol Med. 1975 Jan;148(1):98-103. PubMed PMID: 1168915.

15: Schulz H, Kovács GL, Telegdy G. Action of posterior pituitary neuropeptides on the nigrostriatal dopaminergic system. Eur J Pharmacol. 1979 Aug 1;57(2-3):185-90. PubMed PMID: 573691.

16: Davis JL, Pico RM, Cherkin A. Memory enhancement induced in chicks by L-prolyl-L-leucyl-glycinamide. Pharmacol Biochem Behav. 1982 Nov;17(5):893-6. PubMed PMID: 6129646.

17: Postina R, Kojro E, Fahrenholz F. Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling. Adv Exp Med Biol. 1998;449:371-85. Review. PubMed PMID: 10026828.

18: Manberg PJ, Youngblood WW, Kizer JS. Development of a radioimmunoassay for Pro-Leu-Gly-NH2 (PLG or MIF-I): evidence that PLG is not present in rat brain. Brain Res. 1982 Jun 10;241(2):279-84. PubMed PMID: 6125241.

19: Versteeg CA, Bohus B, de Jong W. Inhibition of centrally-evoked pressor responses by neurohypophyseal peptides and their fragments. Neuropharmacology. 1982 Dec;21(12):1359-64. PubMed PMID: 7155315.

20: Ehrensing RH, Michell GF, Kastin AJ. Similar antagonism of morphine analgesia by MIF-1 and naloxone in Carassius auratus. Pharmacol Biochem Behav. 1982 Oct;17(4):757-61. PubMed PMID: 6129644.